#InTheNews: Our Chief Commercial Officer Hylton Kalvaria speaks with Drug Target Review about the benefits of sequencing hundreds of thousands of participants to create datasets that integrate genomic and clinical data for GLP-1s: bit.ly/3WyzaS6

#InTheNews: The Ohio State University Wexner Medical Center will launch the Ohio State Genomic Health program with Helix later in 2024, enrolling 100,000 participants at no cost to screen for variants associated with high cholesterol and various cancers. Read more details from Becker's Hospital Review: bit.ly/4fmcj4N

#WorldLungCancerDay. We stand united against #LungCancer by bringing ultra-precise MRD testing to patients with early-stage NSCLC. Learn about a study with 170+ patients, where we detected lung cancer recurrence, on median, about 6 months ahead of scans: bit.ly/40xPiVg

Stock markets worldwide have been volatile after the "Sahm rule" recession indicator went off. Varo's Head of Public Policy & Impact, Corey Carlisle, spoke to Jessica Roy at @SFChronicle to warn against making rash decisions based on fluctuation: sfchronicle.com/bayarea/articl…

Few doctors have seen #StiffPersonSyndrome, let alone know how to treat it. Kyverna’s business unit head of rare diseases, Sham Dholakia, recently spoke with Business Insider about the challenges in diagnosing SPS. businessinsider.com/stiff-person-s…

Our latest webinar is here to guide you through the basics of getting started with single-cell DNA sequencing! On 8/20, join our expert Rachel where she'll provide an overview of the technology, workflow and getting started, and data analysis Register ➡️ bit.ly/3LZVuik

With the recent filing of our Class VI permit in Wyoming, Spiritus is well on its way to beginning carbon removal operations at Orchard One in 2026. Learn more about today’s announcement in Carbon Herald: carbonherald.com/spiritus-files…

In case you missed this recent op-ed in Technology Networks! Our SVP of Research and Tech Development, Asim Siddiqui, Ph.D., offers thoughtful insights into the crucial role of unbiased #proteomics in advancing clinical #biomarkerdiscovery. bit.ly/3YuCgZL

We’re thrilled to announce our latest step forward in advancing the field of infectious disease diagnostics: A contract with BARDA that supports the extension of our capabilities to include RNA pathogen detection. Read more here: hubs.li/Q02KF_pB0? #metagenomics #HHS

Pleased to share we have received our second U.S. FDA RMAT Designation for #KYV101 in the treatment of patients with progressive myasthenia gravis. prnewswire.com/news-releases/…

Dr. Richard Chen highlights NeXT Personal®, an ultra-sensitive minimal residual disease (MRD) test, in article from Biocompare. NeXT Personal has been shown to detect early-stage lung and breast cancer recurrence months before cancer was seen on scans: bit.ly/3yJdivi.

Published today in Frontiers, researchers utilized Mission Bio's Genome Editing Solution for characterizing their triple gene-edited cell therapy, revealing heterogeneity in the combinations of on-target and off-target edits made in each cell. frontiersin.org/journals/bioen…

With $54M announced, #Openwater has reached the $100M in total to commercialize its platform. Axios has more on Openwater's platform outperforming prehospital stroke scales in detecting large vessel occlusion in stroke patients. axios.com/pro/health-tec…

ICYMI: Earlier, we announced expansion of our commercial relationship with Tempus. Following strong demand of our ultra-sensitive MRD product, both companies have agreed to accelerate efforts, including Tempus investing ~ $36 million into Personalis: bit.ly/3X8GqV4

Proud to have been the 'Featured Presenter' at the Cell Therapy Manufacturing session during the 16th Annual Bioprocessing Summit in Boston last week. The event brought together leaders from industry and academia, where our clinical product data saw significant interest. #kyv101

Openwater aims to transform healthcare with a $100m open-source, drug-free tech. Leveraging semiconductor physics plus light & sound, it diagnoses and treats diseases at the cellular level. Mary Lou Jepsen, PhD Peter Gabriel #longevity #investment #healthcare bit.ly/4e1yE5R

📢 Excited to share our findings at #WCLC24! Our research led by Arutha K reveals a metabolic signature tied to #immunotherapy resistance and survival in #LungCancer patients, paving the way for predictive #biomarkers for #ICIs. bit.ly/4ghOk7e

Europe and the UK, welcome back to the lab! First week back? Kickstart your research with a chance to win $750 in tips and labware! Participate in our survey and you could be one of the five lucky winners. Help us refine our products by sharing your feedback. Ready to win? Fill

We're pleased to see scientists making novel biological discoveries with the #Proteograph. We'd love to connect with you at Biomarkers Series #BiomarkersEU24 and explore how #unbiasedproteomics and our technology could help advance your work. Seer's Booth #16. bit.ly/3AShOZ9

We were honored to host @BLOOD_PAC’s Q3 in-person meeting last week! This event brought together industry leaders accelerating the development, validation and accessibility of liquid biopsy assays to improve the outcomes of patients with cancer. #LiquidBiopsy #PrecisionOncology